文献速递肿瘤 PET/CT骨显像与常规 SPECT核素与放射性配体治疗

PSMA/FAPI双特异性示踪剂¹⁸F-ALF-NOTA-PSFA-1与¹⁸F-FDG PET/CT在骨原发透明细胞肉瘤检测中的比较

Comparison of PSMA/FAPI Bispecific Tracer ¹⁸F-ALF-NOTA-PSFA-1 and ¹⁸F-FDG PET/CT in the Detection of Primary Clear Cell Sarcoma of Bone.
PubMed 文献 · Clin Nucl Med · 2026-03-24

一例43岁男性左髋痛患者,增强CT示左侧髂骨及骶骨溶骨性破坏伴软组织延伸,提示骨肿瘤。¹⁸F-FDG PET/CT仅见髂骨、骶骨及右腓骨病灶轻度或无FDG摄取,而PSMA/FAPI双特异性示踪剂¹⁸F-ALF-NOTA-PSFA-1 PET/CT上这些病灶呈浓密或增高摄取。提示¹⁸F-ALF-NOTA-PSFA-1 PET/CT对肉瘤检测有潜力,并可能支持PSMA/FAPI双特异性靶向受体放射性核素治疗的发展。

要点

  • 骨原发透明细胞肉瘤在¹⁸F-FDG PET/CT上可表现为轻度或无摄取。
  • PSMA/FAPI双特异性示踪剂¹⁸F-ALF-NOTA-PSFA-1在病灶中呈浓密或增高摄取。
  • 该示踪剂可能支持PSMA/FAPI双特异性靶向受体放射性核素治疗的开发。

核心结论

  • ¹⁸F-ALF-NOTA-PSFA-1 PET/CT对肉瘤检测有相当潜力,并可能支持PSMA/FAPI双特异性靶向受体放射性核素治疗的发展。

研究设计与样本

  • 单例43岁男性病例报告,因左髋痛就诊,行增强CT、¹⁸F-FDG PET/CT及¹⁸F-ALF-NOTA-PSFA-1 PET/CT检查。

主要发现

  • 增强CT示左侧髂骨及骶骨溶骨性破坏伴软组织延伸,提示骨肿瘤。
  • ¹⁸F-FDG PET/CT示髂骨、骶骨及右腓骨病灶仅轻度或无FDG摄取。
  • ¹⁸F-ALF-NOTA-PSFA-1 PET/CT示上述病灶浓密或增高摄取。

临床怎么用

  • 对FDG摄取不高但仍怀疑骨肉瘤的病灶,可考虑PSMA/FAPI双特异性示踪剂PET/CT辅助检测。

局限性

  • 仅为单例病例报告,结论需更大样本研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 43-year-old man presented with left hip pain. Contrast-enhanced CT demonstrated lytic destruction of the left ilium and sacrum with associated soft-tissue extension, suggestive of a bone tumor. Subsequent ¹⁸F-FDG PET/CT revealed only mild or no FDG avidity in lesions involving the ilium, sacrum, and right fibula. In contrast, these lesions demonstrated intense or elevated uptake on PSMA/FAPI bispecific tracer ¹⁸F-ALF-NOTA-PSFA-1 PET/CT. These observations indicate that ¹⁸F-ALF-NOTA-PSFA-1 PET/CT holds considerable potential for sarcoma detection and may support the development of PSMA/FAPI bispecific targeted receptor radionuclide therapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Wu J, Gao H, He L, et al. Comparison of PSMA/FAPI Bispecific Tracer ¹⁸F-ALF-NOTA-PSFA-1 and ¹⁸F-FDG PET/CT in the Detection of Primary Clear Cell Sarcoma of Bone. Clin Nucl Med. 2026. PMID: 41941244. doi:10.1097/RLU.0000000000006421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。